Bunion Clinical Trial
— STRIDEOfficial title:
A Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupivacaine vs. Bupivacaine Only Administered as Combined Sciatic (in Popliteal Fossa) and Adductor Canal Nerve Block for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries
Verified date | May 2020 |
Source | Pacira Pharmaceuticals, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 3, multicenter, randomized, double blinded, active controlled study in approximately 81 subjects undergoing lower extremity surgeries with combined sciatic and adductor canal nerve block.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2020 |
Est. primary completion date | September 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Healthy adult male or female volunteers ages 18 or older 2. American Society of Anesthesiologists (ASA) physical status 1, 2 or 3. 3. Able to provide informed consent, adhere to the study schedule, and complete all study assessments. 4. Body Mass Index =18 and =40 kg/m2 Exclusion Criteria: 1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids, bupivacaine, NSAIDs) 2. Documented history of long-term diabetes, renal (serum creatinine level >2mg/dL [176.8 µmol/L]) or hepatic dysfunction (serum alanine or aspartame transferase > 3 times the upper limit of normal), coagulation or bleeding disorder and severe peripheral vascular disease 3. Concurrent painful physical condition that may require analgesic treatment (such as long-term, consistent use of opioids) in the post dosing period for pain and which, in the investigator's opinion may confound the post dosing assessments 4. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years 5. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study 6. Previous participation in EXPAREL study 7. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance 8. Currently pregnant, nursing, or planning to become pregnant during the study 9. Clinically significant medical disease that, in the opinion of the investigator, would make participation in a clinical study inappropriate. This includes any psychiatric or other conditions that would constitute a contraindication to participation in the study 10. Currently on neuroleptic agent [e.g., gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) etc.] 11. Inadequate sensory function on the foot (monofilament test) 12. Chronic opioid use in the last 30 days (=30 morphine equivalents/ day) In addition, the subject may be withdrawn from the study if the subject meets the following criterion during or post-surgery: 13. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that, in the opinion of the investigator, renders the subject medically unstable or complicates the subject's post-operative course |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pacira Pharmaceuticals, Inc |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Magnitude of analgesic effect | Area under the Curve of the NRS Pain intensity scores from 0 hours to 96 hours post-surgery. | 0 hours to 96 hours | |
Secondary | Total Postsurgical Opioid Consumption | Total Postsurgical opioid consumption from 0 hours to 96 hours post-surgery | 0 hours to 96 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01435577 -
Intravenous Tapentadol in Post-Bunionectomy Pain
|
Phase 2 | |
Terminated |
NCT05082012 -
Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D)
|
N/A | |
Terminated |
NCT03257540 -
Early Weight-Bearing After Lapidus Arthrodesis
|
||
Completed |
NCT04518462 -
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries
|
Phase 3 | |
Completed |
NCT04084262 -
Multi-Plane Hallux Valgus Correction With the Phantom® Nail
|
||
Active, not recruiting |
NCT03740282 -
Early Weight-Bearing After the Lapiplasty Procedure
|
N/A | |
Completed |
NCT01743625 -
Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain
|
Phase 3 | |
Completed |
NCT01484652 -
Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension
|
Phase 3 | |
Recruiting |
NCT05831449 -
CPL-01 in the Management of Postoperative Pain After Bunionectomy
|
Phase 3 | |
Terminated |
NCT01133639 -
Ketorolac Effects on Post-operative Pain and Bone Healing
|
N/A | |
Completed |
NCT04826328 -
Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy
|
Phase 1 | |
Recruiting |
NCT05773846 -
A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain
|
Phase 3 | |
Completed |
NCT03653429 -
Efficacy of Tranexamic Acid in Foot and Ankle Surgeries
|
Phase 4 | |
Recruiting |
NCT04751344 -
Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery
|
Phase 4 | |
Completed |
NCT04002089 -
Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy
|
Phase 1 | |
Terminated |
NCT02499575 -
Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures
|
N/A | |
Completed |
NCT00613938 -
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.
|
Phase 3 | |
Completed |
NCT03246971 -
Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain
|
Phase 2 | |
Completed |
NCT00890682 -
Study of Postoperative Analgesia in Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05602844 -
Clinical Trial on Patient-Specific-Instrumentation Assisted Lapidus Fusion for Hallux Valgus
|
N/A |